Proceedings of the 1st biannual bridging the gaps in lung cancer conference

Narjust Florez; Sandip P. Patel; Heather Wakelee; Lyudmila Bazhenova; Erminia Massarelli; Ravi Salgia; Brendon Stiles; Solange Peters; Jyoti Malhotra; Shirish M. Gadgeel; Jorge J. Nieva; Michelle Afkhami; Fred R. Hirsch; Matthew Gubens; Tina Cascone; Benjamin Levy; Joshua Sabari; Hatim Husain; Patrick C. Ma; Leah M. Backhus; Puneeth Iyengar; Percy Lee; Russell Miller; Jacob Sands; Edward Kim

doi:10.1093/oncolo/oyae228

Proceedings of the 1st biannual bridging the gaps in lung cancer conference

Narjust Florez, Sandip P. Patel, Heather Wakelee, Lyudmila Bazhenova, Erminia Massarelli, Ravi Salgia, Brendon Stiles, Solange Peters, Jyoti Malhotra, Shirish M. Gadgeel, Jorge J. Nieva, Michelle Afkhami, Fred R. Hirsch, Matthew Gubens, Tina Cascone, Benjamin Levy, Joshua Sabari, Hatim Husain, Patrick C. Ma, Leah M. BackhusPuneeth Iyengar, Percy Lee, Russell Miller, Jacob Sands, Edward Kim

Research output: Contribution to journal › Article › peer-review

Abstract

Lung cancer is the leading cause of cancer death in the US and globally. The mortality from lung cancer has been declining, due to a reduction in incidence and advances in treatment. Although recent success in developing targeted and immunotherapies for lung cancer has benefitted patients, it has also expanded the complexity of potential treatment options for health care providers. To aid in reducing such complexity, experts in oncology convened a conference (Bridging the Gaps in Lung Cancer) to identify current knowledge gaps and controversies in the diagnosis, treatment, and outcomes of various lung cancer scenarios, as described here. Such scenarios relate to biomarkers and testing in lung cancer, small cell lung cancer, EGFR mutations and targeted therapy in non-small cell lung cancer (NSCLC), early-stage NSCLC, KRAS/BRAF/MET and other genomic alterations in NSCLC, and immunotherapy in advanced NSCLC.

Original language	English (US)
Article number	oyae228
Journal	Oncologist
Volume	30
Issue number	2
DOIs	https://doi.org/10.1093/oncolo/oyae228
State	Published - Feb 1 2025

All Science Journal Classification (ASJC) codes

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/oncolo/oyae228

Cite this

Florez, N., Patel, S. P., Wakelee, H., Bazhenova, L., Massarelli, E., Salgia, R., Stiles, B., Peters, S., Malhotra, J., Gadgeel, S. M., Nieva, J. J., Afkhami, M., Hirsch, F. R., Gubens, M., Cascone, T., Levy, B., Sabari, J., Husain, H., Ma, P. C., ... Kim, E. (2025). Proceedings of the 1st biannual bridging the gaps in lung cancer conference. Oncologist, 30(2), Article oyae228. https://doi.org/10.1093/oncolo/oyae228

@article{9eeaf5b220e84f968ebe533e81ab7524,

title = "Proceedings of the 1st biannual bridging the gaps in lung cancer conference",

abstract = "Lung cancer is the leading cause of cancer death in the US and globally. The mortality from lung cancer has been declining, due to a reduction in incidence and advances in treatment. Although recent success in developing targeted and immunotherapies for lung cancer has benefitted patients, it has also expanded the complexity of potential treatment options for health care providers. To aid in reducing such complexity, experts in oncology convened a conference (Bridging the Gaps in Lung Cancer) to identify current knowledge gaps and controversies in the diagnosis, treatment, and outcomes of various lung cancer scenarios, as described here. Such scenarios relate to biomarkers and testing in lung cancer, small cell lung cancer, EGFR mutations and targeted therapy in non-small cell lung cancer (NSCLC), early-stage NSCLC, KRAS/BRAF/MET and other genomic alterations in NSCLC, and immunotherapy in advanced NSCLC.",

author = "Narjust Florez and Patel, \{Sandip P.\} and Heather Wakelee and Lyudmila Bazhenova and Erminia Massarelli and Ravi Salgia and Brendon Stiles and Solange Peters and Jyoti Malhotra and Gadgeel, \{Shirish M.\} and Nieva, \{Jorge J.\} and Michelle Afkhami and Hirsch, \{Fred R.\} and Matthew Gubens and Tina Cascone and Benjamin Levy and Joshua Sabari and Hatim Husain and Ma, \{Patrick C.\} and Backhus, \{Leah M.\} and Puneeth Iyengar and Percy Lee and Russell Miller and Jacob Sands and Edward Kim",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2025",

month = feb,

day = "1",

doi = "10.1093/oncolo/oyae228",

language = "English (US)",

volume = "30",

journal = "Oncologist",

issn = "1083-7159",

publisher = "Oxford University Press",

number = "2",

}

Florez, N, Patel, SP, Wakelee, H, Bazhenova, L, Massarelli, E, Salgia, R, Stiles, B, Peters, S, Malhotra, J, Gadgeel, SM, Nieva, JJ, Afkhami, M, Hirsch, FR, Gubens, M, Cascone, T, Levy, B, Sabari, J, Husain, H, Ma, PC, Backhus, LM, Iyengar, P, Lee, P, Miller, R, Sands, J & Kim, E 2025, 'Proceedings of the 1st biannual bridging the gaps in lung cancer conference', Oncologist, vol. 30, no. 2, oyae228. https://doi.org/10.1093/oncolo/oyae228

TY - JOUR

T1 - Proceedings of the 1st biannual bridging the gaps in lung cancer conference

AU - Florez, Narjust

AU - Patel, Sandip P.

AU - Wakelee, Heather

AU - Bazhenova, Lyudmila

AU - Massarelli, Erminia

AU - Salgia, Ravi

AU - Stiles, Brendon

AU - Peters, Solange

AU - Malhotra, Jyoti

AU - Gadgeel, Shirish M.

AU - Nieva, Jorge J.

AU - Afkhami, Michelle

AU - Hirsch, Fred R.

AU - Gubens, Matthew

AU - Cascone, Tina

AU - Levy, Benjamin

AU - Sabari, Joshua

AU - Husain, Hatim

AU - Ma, Patrick C.

AU - Backhus, Leah M.

AU - Iyengar, Puneeth

AU - Lee, Percy

AU - Miller, Russell

AU - Sands, Jacob

AU - Kim, Edward

PY - 2025/2/1

Y1 - 2025/2/1

N2 - Lung cancer is the leading cause of cancer death in the US and globally. The mortality from lung cancer has been declining, due to a reduction in incidence and advances in treatment. Although recent success in developing targeted and immunotherapies for lung cancer has benefitted patients, it has also expanded the complexity of potential treatment options for health care providers. To aid in reducing such complexity, experts in oncology convened a conference (Bridging the Gaps in Lung Cancer) to identify current knowledge gaps and controversies in the diagnosis, treatment, and outcomes of various lung cancer scenarios, as described here. Such scenarios relate to biomarkers and testing in lung cancer, small cell lung cancer, EGFR mutations and targeted therapy in non-small cell lung cancer (NSCLC), early-stage NSCLC, KRAS/BRAF/MET and other genomic alterations in NSCLC, and immunotherapy in advanced NSCLC.

AB - Lung cancer is the leading cause of cancer death in the US and globally. The mortality from lung cancer has been declining, due to a reduction in incidence and advances in treatment. Although recent success in developing targeted and immunotherapies for lung cancer has benefitted patients, it has also expanded the complexity of potential treatment options for health care providers. To aid in reducing such complexity, experts in oncology convened a conference (Bridging the Gaps in Lung Cancer) to identify current knowledge gaps and controversies in the diagnosis, treatment, and outcomes of various lung cancer scenarios, as described here. Such scenarios relate to biomarkers and testing in lung cancer, small cell lung cancer, EGFR mutations and targeted therapy in non-small cell lung cancer (NSCLC), early-stage NSCLC, KRAS/BRAF/MET and other genomic alterations in NSCLC, and immunotherapy in advanced NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=86000585818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=86000585818&partnerID=8YFLogxK

U2 - 10.1093/oncolo/oyae228

DO - 10.1093/oncolo/oyae228

M3 - Article

C2 - 39237103

AN - SCOPUS:86000585818

SN - 1083-7159

VL - 30

JO - Oncologist

JF - Oncologist

IS - 2

M1 - oyae228

ER -

Proceedings of the 1st biannual bridging the gaps in lung cancer conference

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this